With an FDA-cleared innovative technology and a $14 price target, NRXS is an IPO with blue-sky potential.

Greetings Investors,

The global medical device market has a staggering size of over $500 billion. What’s even more impressive is that it’s expected to grow to over $800 billion by 2032.

Interest in this space may certainly intensify in the coming years and finding the companies that stand out now may be the most opportunistic.

Quickly get your eyes on NeurAxis, Inc. (NYSE: NRXS).

The company successfully completed its IPO and NYSE listing in August and may about to cause quite a commotion on Wall Street!

An analyst has said this IPO is “too compelling to ignore” and you may agree yourself after reading everything that this company has going on….

https://neuraxis.com/

Trading at around $5, NRXS is a growing NYSE med-tech company that is commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults.

Neuromodulation treatments encompass a growing variety of methods that target the brain or nervous system at specific locations in the body.

Today, neuromodulation therapy is no longer a treatment of last resort. In fact, in its earlier implementation may even modify the trajectory of some chronic conditions.

Who are the players in the neuromodulation market?

The key players operating in the global neuromodulation market include Abbott, Boston Scientific Corporation, and Medtronic.

Could NRXS quickly rise to the ranks of these big players whose market caps are in the billions?


The stock currently has a “BULLISH” rating at StockTA.com and a $14 price target!

NeurAxis Has Earned a $14 Price Target from an Esteemed Analyst Based on The Company’s Potential to Revolutionize Pediatric FAP and IBS Treatments!

An analyst report from Goldman Smallcap Research (GSCR) on August 11th, 2023, models NRXS shares reaching $14 in the next six to twelve months.

Highlights from the report include:

  • NRXS is well-positioned to revolutionize treatment strategies for children and adults who suffer from chronic and debilitating conditions.
  • First mover advantage can be transformative as the company has a robust IP portfolio, over 700 patient reports, and a number of publications supporting NRXS technology as a best-in-class treatment option. This could drive potentially exponential revenue growth.
  • NRXS has at least four major carriers providing payer coverage and more expected this year, trying to compete against the company may be challenging or even futile, especially for companies committed to using f-label pharmaceutical use to treat the same indications.
  • GSCR’s revenue estimates for NRXS to reach $22 millionby 2025 could fall on the conservative side. 
  • NRXS technology can be a treatment game-changer. And while patients will ultimately benefit from an improved standard of care, the company and its investors also stand to gain appreciably. 
  • NRXS is advancing its prospective, randomized, double-blind study for post-concussion syndrome at Children’s Hospital of Orange County. The company noted that additional site(s) could be added to strengthen the research data and expedite NRXS targeting a $1.9 billionmarket opportunity from the estimated 400,000 patients diagnosed annually. 

You can read the full report HERE.

Company Overview:

NRXS is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities.

“A New Standard of Care”

https://ibstim.com/

The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain (FAP) associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.

Excitingly the IB-Stim™ is already FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old!

The company has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology. Sales began after the company had received the FDA clearance.

Brian Carrico, Chief Executive Officer commented, “We are pleased to have reached over $8 million in sales of our proprietary IB-Stim™ technology and look forward building upon our momentum with the funds received from our recently completed IPO. We continue to drive increasing adoption of our IB-Stim™ therapy, supported by a significant and growing body of positive clinical data and commercial large health insurance company payor support. We believe the growing movement of patients gravitating towards non drug related therapies, especially for children, will continue to fuel our rapidly increasing adoption and the market for our new indications.”

This is finally a non-drug alternative to reducing functional abdominal pain in patients who have IBS.

IBS, also known as spastic colon, colitis, nervous colon, and spastic bowel, is the most common cause of recurrent abdominal pain in children: 10 percent to 15 percent of children have IBS at some point.

NRXS’s IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear.

This stimulation targets brain areas involved in processing pain and aids in the reduction of functional abdominal pain associated with IBS.

Parents are leaving testimonials with NRXS that showcase how this technology has radically changed their hurting children’s lives.

NRXS is also conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.

In Summary….

NRXS’s IPO has been years in the making and it’s finally here!

Goldman Small Cap Research’s 6-12-month price target is $14 and is more than double the IPO price.

Goldman commented, “This newly trading IPO is too compelling to ignore. We believe NRXS is poised to revolutionize treatment strategies for children and adults who suffer from chronic and debilitating conditions. The Company boasts a first-mover advantage, strong IP, a total addressable market of $30B, and an FDA-cleared product that serves a major need in a badly underserved market. Plus, future, exponential top-line growth appears to be driven by a series of new insurance companies payer coverages, which exponentially increases the market opportunity with each new insurer.”

This may be the best time to have NRXS high on your radar! Start your research!

Disclaimer:

This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. WallStreetNation.com, owned and operated by Jade Cabbage Media, LLC d/b/a STOXmedia.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold, or held by viewers that learn of the profiled companies through our website. 

 
Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for in an effort to enhance public awareness of NeurAxis Inc. and its securities. Jade Cabbage Media, LLC d/b/a STOXmedia.com has received up to $10,000 USD dollars by Winning Media LLC as a total production budget for this advertising effort. Neither WallStreetNation.com, Winning Media LLC or Jade Cabbage Media LLC currently hold the securities of NeurAxis Inc. and do not currently intend to purchase such securities. 
 
Winning Media LLC has been compensated the sum total of forty thousand dollars USD total production budget to manage a digital media campaign for fourteen days by One Eyed Jack Media LLC. on 8/23/23.
 
This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are several important factors that could cause actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues, and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. 
 
More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at the SEDAR and/or SEC’s EDGAR page. Jade Cabbage Media, LLC d/b/a STOXmedia.com is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.